Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 47.96
NVO's Cash to Debt is ranked higher than
73% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. NVO: 47.96 )
NVO' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 47.96

Equity to Asset 0.53
NVO's Equity to Asset is ranked higher than
65% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVO: 0.53 )
NVO' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.73
Current: 0.53

0.51
0.73
Interest Coverage 572.60
NVO's Interest Coverage is ranked higher than
56% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 572.60 )
NVO' s 10-Year Interest Coverage Range
Min: 4.79   Max: 572.6
Current: 572.6

4.79
572.6
F-Score: 8
Z-Score: 16.90
M-Score: -2.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.05
NVO's Operating margin (%) is ranked higher than
97% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. NVO: 38.05 )
NVO' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 37.77
Current: 38.05

10.5
37.77
Net-margin (%) 30.27
NVO's Net-margin (%) is ranked higher than
96% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. NVO: 30.27 )
NVO' s 10-Year Net-margin (%) Range
Min: 10.59   Max: 30.13
Current: 30.27

10.59
30.13
ROE (%) 68.47
NVO's ROE (%) is ranked higher than
99% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. NVO: 68.47 )
NVO' s 10-Year ROE (%) Range
Min: 11.34   Max: 60.54
Current: 68.47

11.34
60.54
ROA (%) 38.62
NVO's ROA (%) is ranked higher than
99% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. NVO: 38.62 )
NVO' s 10-Year ROA (%) Range
Min: 7.57   Max: 37.03
Current: 38.62

7.57
37.03
ROC (Joel Greenblatt) (%) 131.48
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. NVO: 131.48 )
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 126.76
Current: 131.48

6.89
126.76
Revenue Growth (3Y)(%) 14.30
NVO's Revenue Growth (3Y)(%) is ranked higher than
87% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NVO: 14.30 )
NVO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.3   Max: 23
Current: 14.3

0.3
23
EBITDA Growth (3Y)(%) 19.00
NVO's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NVO: 19.00 )
NVO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 8.4   Max: 25.7
Current: 19

8.4
25.7
EPS Growth (3Y)(%) 23.90
NVO's EPS Growth (3Y)(%) is ranked higher than
91% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NVO: 23.90 )
NVO' s 10-Year EPS Growth (3Y)(%) Range
Min: 10.3   Max: 29.7
Current: 23.9

10.3
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NVO Guru Trades in Q4 2013

Murray Stahl 7,740 sh (+400%)
Ruane Cunniff 62,194 sh (+58.71%)
Jim Simons 3,263,700 sh (+4.07%)
Ken Fisher 2,710,787 sh (+0.29%)
Mario Gabelli 1,704 sh (unchged)
Tom Gayner 221,200 sh (-0.23%)
Steven Cohen 3,141 sh (-48.53%)
» More
Q1 2014

NVO Guru Trades in Q1 2014

Ken Fisher 13,631,979 sh (+0.58%)
Jim Simons 16,079,800 sh (-1.46%)
Tom Gayner 1,075,000 sh (-2.8%)
Mario Gabelli 7,665 sh (-10.04%)
Ruane Cunniff 242,630 sh (-21.98%)
Steven Cohen 9,962 sh (-36.57%)
Murray Stahl 7,740 sh (-80%)
» More
Q2 2014

NVO Guru Trades in Q2 2014

Jim Simons 16,953,000 sh (+5.43%)
Ken Fisher 13,741,529 sh (+0.8%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli 7,620 sh (-0.59%)
Ruane Cunniff 160,492 sh (-33.85%)
» More
Q3 2014

NVO Guru Trades in Q3 2014

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ken Fisher 13,385,913 sh (-2.59%)
Jim Simons 16,106,100 sh (-5%)
Mario Gabelli 6,720 sh (-11.81%)
Ruane Cunniff 75,642 sh (-52.87%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2014-09-30 Reduce -52.87%0.02%$43.9 - $49.03 $ 43.81-5%75642
Ruane Cunniff 2014-06-30 Reduce -33.85%0.02%$42.28 - $46.52 $ 43.81-1%160492
Ruane Cunniff 2014-03-31 Reduce -21.98%0.01%$36.722 - $48.23 $ 43.813%242630
Ruane Cunniff 2013-12-31 Add 58.71%0.02%$32.72 - $36.886 $ 43.8126%62194
Ruane Cunniff 2013-06-30 New Buy0.04%$30.11 - $35.33 $ 43.8132%34640
Mario Gabelli 2013-03-31 Reduce -60.32%$32.24 - $38.86 $ 43.8125%1734
John Hussman 2012-09-30 Sold Out 0.01%$28.83 - $32.15 $ 43.8143%0
Ken Fisher 2012-06-30 Add 519.97%1.01%$25.98 - $30.38 $ 43.8154%2786828
John Hussman 2012-03-31 Reduce -40%$23.09 - $28.94 $ 43.8176%3000
Mario Gabelli 2011-12-31 Add 66.87%$18.92 - $23.05 $ 43.81104%5590
John Hussman 2011-09-30 New Buy0.01%$19.46 - $25.45 $ 43.8197%5000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novo Nordisk A/S

Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN
According to GuruFocus list of 52-week highs; Actavis PLC, Novo Nordisk A/S, NXP Semiconductor NV and Wynn Resorts Ltd. have all reached their 52 week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.10
NVO's P/E(ttm) is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 27.10 )
NVO' s 10-Year P/E(ttm) Range
Min: 12.11   Max: 32.39
Current: 27.1

12.11
32.39
P/B 18.37
NVO's P/B is ranked higher than
61% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. NVO: 18.37 )
NVO' s 10-Year P/B Range
Min: 3.41   Max: 20.87
Current: 18.37

3.41
20.87
P/S 8.19
NVO's P/S is ranked higher than
84% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. NVO: 8.19 )
NVO' s 10-Year P/S Range
Min: 2.81   Max: 8.9
Current: 8.19

2.81
8.9
PFCF 26.87
NVO's PFCF is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 26.87 )
NVO' s 10-Year PFCF Range
Min: 12.1   Max: 47.01
Current: 26.87

12.1
47.01
EV-to-EBIT 21.97
NVO's EV-to-EBIT is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 21.97 )
NVO' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 26.1
Current: 21.97

9.1
26.1
PEG 1.22
NVO's PEG is ranked higher than
99% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 1.22 )
NVO' s 10-Year PEG Range
Min: 0.54   Max: 1.66
Current: 1.22

0.54
1.66
Shiller P/E 38.67
NVO's Shiller P/E is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 38.67 )
NVO' s 10-Year Shiller P/E Range
Min: 18.94   Max: 43.15
Current: 38.67

18.94
43.15
Current Ratio 1.37
NVO's Current Ratio is ranked higher than
55% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NVO: 1.37 )
NVO' s 10-Year Current Ratio Range
Min: 1.31   Max: 2.88
Current: 1.37

1.31
2.88
Quick Ratio 1.00
NVO's Quick Ratio is ranked higher than
53% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NVO: 1.00 )
NVO' s 10-Year Quick Ratio Range
Min: 0.92   Max: 2.34
Current: 1

0.92
2.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.38
NVO's Dividend Yield is ranked higher than
78% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NVO: 1.38 )
NVO' s 10-Year Dividend Yield Range
Min: 0.79   Max: 2.47
Current: 1.38

0.79
2.47
Dividend Payout 0.33
NVO's Dividend Payout is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 0.33 )
NVO' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.61
Current: 0.33

0.51
1.61
Dividend growth (3y) 33.90
NVO's Dividend growth (3y) is ranked higher than
97% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. NVO: 33.90 )
NVO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37.5
Current: 33.9

0
37.5
Yield on cost (5-Year) 4.14
NVO's Yield on cost (5-Year) is ranked higher than
95% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. NVO: 4.14 )
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 2.33   Max: 7.3
Current: 4.14

2.33
7.3
Share Buyback Rate 2.70
NVO's Share Buyback Rate is ranked higher than
98% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. NVO: 2.70 )
NVO' s 10-Year Share Buyback Rate Range
Min: 3   Max: -0.3
Current: 2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.07
NVO's Price/Tangible Book is ranked higher than
65% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. NVO: 19.07 )
NVO' s 10-Year Price/Tangible Book Range
Min: 3.22   Max: 21.28
Current: 19.07

3.22
21.28
Price/DCF (Projected) 3.37
NVO's Price/DCF (Projected) is ranked higher than
94% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 3.37 )
NVO' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 22.47
Current: 3.37

1.3
22.47
Price/Median PS Value 1.71
NVO's Price/Median PS Value is ranked higher than
76% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. NVO: 1.71 )
NVO' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.83
Current: 1.71

0.16
1.83
Price/Peter Lynch Fair Value 1.28
NVO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 1.28 )
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.37
Current: 1.28

0.07
1.37
Price/Graham Number 4.77
NVO's Price/Graham Number is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 4.77 )
NVO' s 10-Year Price/Graham Number Range
Min: 1.6   Max: 5.09
Current: 4.77

1.6
5.09
Earnings Yield (Greenblatt) 4.60
NVO's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. NVO: 4.60 )
NVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.8   Max: 11
Current: 4.6

3.8
11
Forward Rate of Return (Yacktman) 23.75
NVO's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 16.92 vs. NVO: 23.75 )
NVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 36.1
Current: 23.75

1.7
36.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:0QIU.UK, NOVO B.Denmark, NONOF.USA, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland,
Novo-Nordisk A/S was incorporated on 28th November, 1931 in Denmark. It is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products which include glucagon, protein-related delivery systems and needles, obesity and oral antidiabetic drugs. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy, hormone replacement therapy and inflammation.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
Shire PLC: Time to Panic? Feb 07 2014 

More From Other Websites
Business Highlights Dec 19 2014
NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with... Dec 10 2014
Share repurchase programme Dec 10 2014
How To Profit From The Obesity Epidemic Dec 08 2014
Paralegal: Sanofi fired her for whistleblowing Dec 05 2014
Paralegal: Sanofi fired her for whistleblowing Dec 05 2014
A Look At 4 ETFs From The 4 'Least Corrupt' Countries Dec 04 2014
Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million... Dec 01 2014
Share repurchase programme Dec 01 2014
[$$] Novo Could Put Money Where Its Mouth Is Nov 26 2014
Novo Nordisk's Victoza Recommended for Label Expansion Nov 24 2014
Changes in Novo Nordisk's Executive Management Nov 24 2014
Share repurchase programme Nov 24 2014
Sanofi Shakes Off Patent Losses Nov 24 2014
Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal... Nov 21 2014
Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
Share repurchase programme Nov 17 2014
Novo Nordisk second best in the world at providing access to medicine Nov 17 2014
Media Release - Top 100 Employer Nov 04 2014
New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg... Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK